Benchling Stock for Accredited Investors

Biotech / Life Sciences
CEO Sajith Wickramasekara Founded 2012 HQ San Francisco, US

Benchling is a cloud platform for life sciences R&D that helps biotech and pharmaceutical teams manage scientific data, workflows, and collaboration. It is used to standardize lab information and streamline research operations across organizations.

Access to pre-IPO shares is available to accredited investors through UpMarket.

Latest Price
$6.1B
Series F, Nov 2021, Perplexity
UpMarket Estimate
$5.4B
Based on UpMarket valuation model
Previous Price
$4.0B
Series E May 2020

How to Invest in Benchling Through UpMarket

Benchling shares are not on public exchanges. UpMarket provides accredited investors access through secondary market transactions.

Step 01

Verify accredited investor status

Confirm eligibility under SEC Rule 501 of Regulation D. Income or net worth threshold applies.

Step 02

Create an UpMarket account

Complete KYC/AML onboarding. Typically 1–2 business days. Licensed rep assigned on signup.

Step 03

Review available Benchling offerings

Full offering memoranda and risk disclosures provided before any commitment is required.

Step 04

Complete subscription documents

Review and sign subscription agreement. All documents handled digitally through the platform.

Step 05

Fund your investment

Wire transfer or ACH. $50K minimum. Funds held in custodial account until close.

Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.

${{aum_amount_brokered_en}}B+
UpMarket has brokered over ${{aum_amount_brokered_en}} billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through {{aum_as_of_date_en}}. Of the total, approximately ${{aum_amount_managed_en}} million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.

Valuation Growth Over Time

Post-money valuation by round
Previous rounds Most recent
DateRoundPPS (split-adj.)Valuation
Nov 2021 Series F $6.1B
May 2020 Series E $4.0B
Jul 2018 Series D
Sep 2017 Series C
May 2016 Series B

Why Investors Are Watching Benchling

Growth Signal

Benchling reached a $6.1B valuation in latest funding round

Benchling was valued at $6.1 billion after a new funding round led by Altimeter Capital Management, with Franklin Templeton joining as a new investor. The round included $100 million and followed a prior $4 billion valuation in an April fundraising led by Sequoia.

Product Milestone

Benchling raised $200M to scale life sciences R&D cloud

Benchling said its Series E raised $200 million, led by Sequoia Capital Global Equities, to aggressively invest in product development and global expansion. The company described itself as the leading life sciences R&D cloud serving enterprise customers.

Market Opportunity

Benchling revenue reportedly rose from $50M to $225M-$250M

MarketX Ventures reported Benchling revenue surged from $50 million in 2020 to a projected $225 million to $250 million in 2023, implying growth above 70% year over year. The same source also cited Benchling's latest valuation at $6.1 billion.

Interested in Benchling stock? Fill out the form above or sign up directly. Subject to availability. Accredited investors only.

Request access →

Benchling Leadership Team

Sajith Wickramasekara
CEO
Ashu Singhal
President
Richard Wong
CFO

UpMarket Investment Curation Process

  • Full diligence on every offering

    UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.

  • Strategy, fees & legal reviewed in full

    We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers — legal counsel, auditor, administrator, and custodian.

  • Disciplined managers only

    We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.

  • Built around your objectives

    Our goal is to empower you to build a portfolio that best meets your individual investment objectives.

Ready to access institutional-grade private market investments? Unlock private markets

Benchling Stock FAQ

No. As of March 2026, Benchling is a private company and does not trade on any public stock exchange. Accredited investors can access Benchling shares through UpMarket, a FINRA-registered broker-dealer that specializes in pre-IPO investments.

Benchling does not have a public stock price because it is privately held. The most recent known share price comes from its last funding round. Pre-IPO share prices on the secondary market may differ from the last round price depending on supply, demand, and market conditions.

Yes. Accredited investors can indicate interest in Benchling shares through UpMarket by filling out the form on this page or creating an account at upmarket.co. All pre-IPO offerings are subject to availability and require a $50,000 minimum investment. UpMarket is a FINRA-registered broker-dealer and has brokered more than $500M in alternative investments since 2019.

Pre-IPO investments carry significant risks. Benchling shares are illiquid, meaning there is no public market to sell them quickly. There is no guaranteed exit timeline or return. The investment is speculative in nature, and investors should be prepared for the possibility of total loss. Valuations of private companies can fluctuate substantially between funding rounds. Investors should consult their financial advisor and review all offering documents before investing.

In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.

There are two primary exit paths for pre-IPO holdings: selling your shares on the secondary market to another buyer, or holding until the company completes an IPO or is acquired. Both paths are subject to transfer restrictions, company approval (right of first refusal), and market conditions. The timing of any exit is unpredictable, and investors should plan for a multi-year holding period.

The minimum investment for most pre-IPO offerings on UpMarket is $50,000. This amount may vary depending on the specific offering and share availability. There are no fees to create an UpMarket account or browse available investments. Investors only pay transaction-related fees when they complete an investment.

UpMarket's valuation estimate of is derived from a proprietary model that incorporates multiple data sources: funding round data (Caplight), revenue estimates (Sacra), secondary market pricing, and public company comparables. The model applies a private company discount to the public comp multiple to account for illiquidity and information asymmetry. This estimate is not investment advice and may differ substantially from the price at which shares actually trade.

Benchling runs a cloud platform for life sciences R&D that standardizes scientific data, workflows, and collaboration, with a $5.4B valuation and a latest funding-round valuation of $6.1B — accredited investors can access Benchling stock through UpMarket.

Invest in Benchling Request access